Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1)
Introduction
Gastric cancer is the third most common cancer and the second most common cause of cancer-related deaths worldwide. Although, gastric cancer is the most common malignancy in Asia, South America, and Eastern Europe, its rates are declining in North America and in most northern and western European countries.1, 2 In addition to advances in surgical techniques, recent large-scale randomized controlled trials have demonstrated that S-1, an oral fluoropyrimidine, plays an important role in improving the prognosis of patients with advanced gastric cancer.3, 4 S-1 is an oral anticancer drug that combines the pro-fluorouracil drug tegafur, an inhibitor of dihydropyrimidine dehydrogenase, and potassium oxonate in a molar ratio of 1:0.4:1.
To achieve greater improvements following chemotherapy for gastric cancer, S-1 is being used in combination with various anticancer agents. Protein-bound polysaccharide K (PSK), an oral biological response modifier isolated from the cultured mushroom Coriolus versicolor (Family Polyporaceae), has been used as an immunochemotherapeutic agent for the treatment of various cancers.5, 6, 7 It is difficult to evaluate the response to PSK because its efficacy is determined on the basis of antitumor immunoenhancing effects. The neutrophil:lymphocyte ratio (NLR) has been documented not only as a simple index of the systemic inflammatory response, but also as a predictive indicator of prognosis in critically ill patients with malignancy.8, 9
The survival benefits of immunochemotherapy with PSK in addition to S-1 for patients with gastric cancers are not widely accepted. In the present study we analyzed the outcomes of patients with primary gastric cancer treated with a combination of PSK and S-1 compared with patients treated with S-1 alone, and used the NLR as marker of immune function in patients to determine its prognostic significance.
Section snippets
Patients
The present study was a retrospective review of 190 patients with gastric cancer who underwent S-1 chemotherapy between January 2007 and December 2012 at Kochi Medical School. These patients had been pathologically diagnosed with gastric adenocarcinoma following endoscopic biopsy or surgery. Patients who underwent surgery had either a total or distal gastrectomy with standard lymphadenectomy. Patients with a history of other cancer therapy or those who had been treated with other anticancer
Patient characteristics
Table 1 summarizes the clinical characteristics of all patients in the present study. The study cohort comprised 119 men and 71 women with a median age of 68 years (range 56–80 years). Within the patient group, there were 16 cases of Stage I, 39 cases of Stage II, 57 cases of Stage III, and 78 cases of Stage IIIB adenocarcinoma. The incidence of total gastrectomy was significantly higher in the S-1 + PSK group than in the group treated with S-1 alone (55.6% vs. 36.5%, respectively; P = 0.032).
Discussion
In the present study, the OS of patients with advanced gastric cancer was significantly higher for those treated with S-1 + PSK than S-1 alone. Until now, there has been no adequate-sized study reporting on the results of treatment with the combination of PSK and S-1, even though PSK has been used as a non-specific immunostimulant in the treatment of cancer patients in Japan for more than 30 years.12, 13, 14 Previous studies reported that the addition of PSK to chemotherapy with agents such as
References (23)
- et al.
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
Lancet Oncol
(2008) - et al.
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer
Lancet
(1994) - et al.
Blood neutrophil-lymphocyte ratio predicts survival for stages III–IV gastric cancer treated with neoadjuvant chemotherapy
World J Surg Oncol
(2013) - et al.
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world
J Clin Oncol
(2006) - et al.
Global patterns of cancer incidence and mortality rates and trends
Cancer Epidemiol Biomarkers Prev
(2010) - et al.
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
N Engl J Med
(2007) - et al.
Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN): review of development and future perspectives
Surg Today
(2012) - et al.
Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I
Exp Ther Med
(2012) - et al.
Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Findings from three independent clinical trials. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer
Cancer
(1996) - et al.
The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment
Med Oncol
(2010)
The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer
Oncology
Cited by (18)
Rhizopus nigricans polysaccharide activated macrophages and suppressed tumor growth in CT26 tumor-bearing mice
2018, Carbohydrate PolymersCitation Excerpt :These glucans present diverse structures with (1→3)-, (1→4)- and/or (1→6)-linked linear or branched α-glucans, β-glucans and mixed α/β-glucans, and molecular weight ranged from thousands to millions Da (Synytsya & Novak, 2013). As the most studied fungal glucan, β-glucans are considered as potent immunomodulators and responsible for the beneficial effects in the outcome of malignant tumor (Ina, Kataoka, & Ando, 2013; Namikawa et al., 2015). Upon specific interactions with several cell surface receptors, such as toll-like receptor, complement receptor 3 and dectin-1, β-glucans can trigger a wide spectrum of immune responses through various signaling pathway (Brown & Gordon, 2001; Gantner, Simmons, Canavera, Akira, & Underhill, 2003; Thornton, Vetvicka, Pitman, Goldman, & Ross, 1996).
Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies
2023, Current Oncology ReportsHerb-drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: A systematic review
2020, Chinese Medicine (United Kingdom)